PHARMA M&A WAVE SET TO REACH INDIA

While merger-mania is gripping the global pharma industry, a similar trend may soon spill over to the Indian market, with pharma companies quoting at low valuations and saddled with huge debt.

Recently, there have been a spate of deals in the pharma space led by Pfizer Inc's acquisition of Wyeth for $68 billion, followed by the merger of Merck and Schering Plough. Experts believe that Bristol-Myers Squibb may be the next target of an acquisition, and many more deals are inevitable. Back home, there has been speculation about Wockhardt and Piramal Healthcare being potential acquisition targets.

The Times Of India

Daiichi-Ranbaxy may signal Big Pharma-generic deals

Daiichi Sankyo Co Ltd's for control of Ranbaxy Laboratories Ltd that pharmaceutical companies have a major appetite for generic drugmakers despite concerns about differences in their business models.

Reuters
http://in.reuters.com/article/asiaCompanyAndMarkets/
idINN1144380420080611?sp=true

Global pharma MNCs find China tough

Colleen Cheng and Angel Chen, Chinese marketing executives in their 30s, should be the ideal customers for US and European drugmakers. So far, they are a tough sell. Glued to their cell phones at an expensive Beijing restaurant, the working moms would fit in at any cafe in New York or London with their fluent English and stylish clothing. They spend hundreds of dollars monthly on herbs, acupuncture and supplements. What they don’t buy are Western pharmaceuticals, like Johnson & Johnson’s cold medicine Sudafed and Sanofi-Aventis’s sleeping pill Ambien.

The Economic Times
http://economictimes.indiatimes.com/International_Business/
Global_pharma_MNCs_find_China_tough/articleshow/2651177.cms